Viking Therapeutics (NASDAQ: VKTX)
Viking Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Viking Therapeutics Company Info
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
News & Analysis
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now.
2 Beaten-Down Stocks With Incredible Upside Potential
Getting in on the ground floor with these companies might lead to superior returns.
Is Viking Therapeutics the Next Big Biotech Bet?
Viking Therapeutics Posts Wider Q2 Loss
After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead.
Yet another biopharma name has been run through a familiar trading cycle that often ends on a bullish note.
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Why This Weight Loss Drug Company's Stock Surged Today
Valuation
Earnings Transcripts
Viking (VKTX) Q2 2025 Earnings Call Transcript
None
Viking Therapeutics (VKTX) Q2 2022 Earnings Call Transcript
VKTX earnings call for the period ending June 30, 2022.
Viking Therapeutics (VKTX) Q1 2022 Earnings Call Transcript
VKTX earnings call for the period ending March 31, 2022.
Viking Therapeutics (VKTX) Q4 2021 Earnings Call Transcript
VKTX earnings call for the period ending December 31, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.